Technegas Approved at the US National Institutes of Health
| Stock | Cyclopharm Ltd (CYC.ASX) |
|---|---|
| Release Time | 18 Feb 2026, 12:32 p.m. |
| Price Sensitive | Yes |
Technegas Approved at the US National Institutes of Health
- Technegas approved for clinical use at the National Institutes of Health (NIH) in the USA
- NIH is the world's largest hospital dedicated to clinical research and is internationally recognized
- Adoption of Technegas at NIH represents an important milestone in Cyclopharm's US expansion
Cyclopharm Limited (ASX: CYC) has announced that Technegas has been approved for clinical use at the National Institutes of Health (NIH) in Bethesda, Maryland, USA. The NIH Clinical Centre is the world's largest hospital dedicated exclusively to clinical research and is internationally recognised for advancing standards of care across multiple medical disciplines. Adoption of Technegas at NIH represents an important clinical and strategic milestone in Cyclopharm's US expansion. This contract leverages Cyclopharm's five-year Federal Supply Schedule (FSS) agreement announced on 14 March 2025, which provides streamlined procurement access across US federal healthcare institutions. The FSS framework supports the growing number of Technegas installations at US Department of Veterans Affairs (VA) hospitals and US military treatment facilities. The NIH order demonstrates the breadth and strategic value of that federal contracting platform. Technegas will be used for clinical ventilation imaging within NIH's protocol-driven clinical program; however, the importance of this installation extends beyond pulmonary embolism (Beyond PE). NIH's leadership in translational research and protocol-driven clinical investigation provides a highly visible platform to expand utilisation of Technegas in chronic obstructive pulmonary disease (COPD), asthma and small airways disease, interstitial lung disease, oncology-related pulmonary complications, and therapeutic assessment and longitudinal lung function studies.
The NIH installation further strengthens Cyclopharm's US credibility as the Company executes its phased strategy of establishing reference centres and expanding long-term institutional penetration. The NIH-led research frequently shapes multicentre collaboration, clinical guidelines and practice patterns, creating downstream adoption opportunities.